Oncolytics Biotech Inc. — FY 2018 Form 20-F
Reporting period: Year ended December 31, 2018. This is an annual filing, not a standalone fourth-quarter report. Financial statements are prepared under IFRS and presented in Canadian dollars unless noted otherwise.
Business context
Oncolytics is a development-stage biopharmaceutical company focused on pelareorep, an investigational oncolytic virus for cancer treatment. It had no reported revenue for 2018 and said it expects significant losses to continue; commercial viability and regulatory approval remain uncertain.
Financial results and liquidity
| Metric (Cdn$ unless stated) | 2018 | 2017 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | 9.42 million | 9.39 million |
| Operating expense | 7.24 million | 6.21 million |
| Net loss | 17.04 million | 15.62 million |
| Basic and diluted loss per share | 1.06 | 1.12 |
| Cash used in operating activities | 11.92 million | 14.89 million |
| Cash and cash equivalents at year-end | 13.70 million | 11.84 million |
| Working capital | Approximately 11.6 million | Not stated clearly in the supplied text |
| Total assets | 14.87 million | 18.15 million |
| Total liabilities | 8.67 million | 9.87 million |
| Shareholders’ equity | 6.20 million | 8.28 million |
No operating margin is meaningful because the company reported no revenue. The company reported no long-term debt; it stated that it had no debt other than trade accounts payable. Cash equivalents included Cdn$9.98 million in interest-bearing bank deposits earning 2.71% at year-end.
Material changes and financing
- Net loss widened by about Cdn$1.42 million year over year. Operating expenses increased, while R&D expense was broadly flat.
- Operating cash use declined by about Cdn$2.97 million, partly reflecting working-capital changes, including collection of a Cdn$4.77 million Adlai receivable.
- Financing activities provided Cdn$13.30 million, primarily from equity issuance, versus Cdn$12.81 million in 2017. Year-end cash rose by Cdn$1.86 million.
- The company completed a 9.5-for-1 share consolidation in May 2018. It reported 17,399,749 common shares outstanding at year-end and continued to have equity-issuance facilities available.
- The Adlai licensing agreement covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan. The company may receive regulatory and other milestone payments and royalties, but these are contingent; the filing does not report 2018 licensing revenue.
Outlook, risks and unusual items
- Management anticipates significant losses in 2019 and the foreseeable future and expects to need additional financing. Future funding needs depend on clinical progress, development costs and access to capital markets; equity financing could dilute shareholders.
- Clinical development priorities include chemotherapy combinations, immunotherapy combinations and targeted or immunomodulatory combinations. The filing describes encouraging signals from earlier studies, including survival results in metastatic breast and pancreatic cancer, but these are not assurances of efficacy or approval.
- Key risks include clinical-trial failure or delay, regulatory approval, dependence on third parties and a primary U.S. toll manufacturer, manufacturing scale-up, competition, intellectual-property challenges, and foreign-exchange exposure.
- Contractual obligations at year-end totaled Cdn$9.16 million, including Cdn$8.20 million for clinical-trial, manufacturing and collaboration activities expected over the next year, and Cdn$0.96 million in operating leases. A Cdn$1.0 million milestone payment is contingent on the first applicable regulatory approval. Additional royalties may become payable if relevant revenue is received.
- The company recorded Cdn$0.55 million of income-tax expense despite its loss, including tax relating to collection of the Adlai receivable. It reported Cdn$1.42 million in share-based payment expense and a Cdn$0.07 million onerous-lease provision.
- The company believes it was a passive foreign investment company (PFIC) for U.S. tax purposes in 2018 and anticipates it may remain one; this may have adverse U.S. tax consequences for U.S. shareholders.
- Management and the independent auditor concluded that internal control over financial reporting was effective at December 31, 2018. The auditor gave unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Cash runway and financing requirements against the planned clinical, manufacturing and collaboration spending.
- Progress, enrollment and results of key pelareorep trials, and whether early survival signals are confirmed in larger controlled studies.
- Adlai’s development progress and the timing and conditions for any milestone, royalty or sales-based payments.
- Manufacturing supply continuity and the company’s ability to scale production while relying primarily on one U.S. toll manufacturer.
- Potential dilution from equity facilities, outstanding options and warrants, and future capital raises.
- PFIC status and related U.S. shareholder tax reporting implications; consult a tax adviser.